These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2982955)

  • 21. Mechanism of recognition of herpes simplex virus type 1-infected cells by natural killer cells.
    López-Guerrero JA; Alarcón B; Fresno M
    J Gen Virol; 1988 Nov; 69 ( Pt 11)():2859-68. PubMed ID: 2846762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Replication of herpes simplex virus in human T lymphocytes: characterization of the viral target cell.
    Braun RW; Teute HK; Kirchner H; Munk K
    J Immunol; 1984 Feb; 132(2):914-9. PubMed ID: 6317753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct evidence for antibody bipolar bridging on herpes simplex virus-infected cells.
    Van Vliet KE; De Graaf-Miltenburg LA; Verhoef J; Van Strijp JA
    Immunology; 1992 Sep; 77(1):109-15. PubMed ID: 1328043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphocyte transformation and interferon production in human mononuclear cell microcultures for assay of cellular immunity to herpes simplex virus.
    Haahr S; Rasmussen L; Merigan TC
    Infect Immun; 1976 Jul; 14(1):47-54. PubMed ID: 181328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antigen-specific immune-suppressor factor in herpes simplex virus type 2 infections of UV B-irradiated mice.
    Aurelian L; Yasumoto S; Smith CC
    J Virol; 1988 Jul; 62(7):2520-4. PubMed ID: 2836632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific lymphocyte blastogenic responses in children with cytomegalovirus and herpes simplex virus infections acquired early in infancy.
    Pass RF; Dworsky ME; Whitley RJ; August AM; Stagno S; Alford CA
    Infect Immun; 1981 Oct; 34(1):166-70. PubMed ID: 6271679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunity to herpes simplex virus type 2 (HSV-2). I. Development of virus-specific lymphoproliferative and leukocyte migration inhibition factor responses in HSV-2-infected guinea pigs.
    Donnenberg AD; Bell RB; Aurelian L
    Cell Immunol; 1980 Dec; 56(2):526-39. PubMed ID: 6258811
    [No Abstract]   [Full Text] [Related]  

  • 28. Measurement of antibody-mediated binding of human polymorphonuclear leukocytes to HSV-1 infected anchorage fibroblasts.
    Van Kessel KP; Van Kats-Renaud HJ; Van Strijp JA; Visser MR; Verhoef J
    J Immunol Methods; 1986 Apr; 88(1):101-7. PubMed ID: 3007623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up studies on herpes simplex antibodies in the course of cervical cancer. II. Antibodies to surface antigen of Herpes simplex virus infected cells.
    Christenson B; Espmark A
    Int J Cancer; 1976 Mar; 17(3):318-25. PubMed ID: 176115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. History of recurrent mucocutaneous herpes correlates with relatively low interferon production by herpes simplex virus-exposed cultured monocytes.
    Linnavuori KH
    J Med Virol; 1988 May; 25(1):61-8. PubMed ID: 2842448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human T-lymphocyte response in vitro to synthetic peptides of herpes simplex virus glycoprotein D.
    DeFreitas EC; Dietzschold B; Koprowski H
    Proc Natl Acad Sci U S A; 1985 May; 82(10):3425-9. PubMed ID: 2582411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-mediated cytotoxicity to herpes-infected cells in humans: dependence on antibodies.
    Moller-Larsen A; Heron I; Haahr S
    Infect Immun; 1977 Apr; 16(1):43-7. PubMed ID: 194838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Herpes simplex virus (HSV) with cervical cancer by lymphocyte reactivity with HSV-1 and HSV-2 antigens.
    Smith JW; Torres JE; Holmquist ND
    Am J Epidemiol; 1979 Aug; 110(2):141-7. PubMed ID: 223438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
    Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
    Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stimulation of human lymphocytes by Herpes simplex virus antigens.
    Starr SE; Karatela SA; Shore SL; Duffey A; Nahmias AJ
    Infect Immun; 1975 Jan; 11(1):109-12. PubMed ID: 163788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity in vivo.
    Voss LM; David CS; Showalter SD; Paya CV; Leibson PJ
    Int Immunol; 1992 Mar; 4(3):417-20. PubMed ID: 1314641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and characterization of herpes simplex virus type 1 (HSV-1) glycoprotein G (gG) by recombinant vaccinia virus: neutralization of HSV-1 infectivity with anti-gG antibody.
    Sullivan V; Smith GL
    J Gen Virol; 1987 Oct; 68 ( Pt 10)():2587-98. PubMed ID: 2822841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzyme immunoassay for detection of antibodies against herpes simplex virus with the use of different viral antigens.
    Maltseva NN; Zvonarev AYu ; Matsevich GR; Ebralidze LK
    Acta Virol; 1987 May; 31(3):226-33. PubMed ID: 2888286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies to herpes simplex viruses: use in antigenic typing and rapid diagnosis.
    Goldstein LC; Corey L; McDougall JK; Tolentino E; Nowinski RC
    J Infect Dis; 1983 May; 147(5):829-37. PubMed ID: 6302177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans.
    Mertz GJ; Peterman G; Ashley R; Jourden JL; Salter D; Morrison L; McLean A; Corey L
    J Infect Dis; 1984 Aug; 150(2):242-9. PubMed ID: 6088648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.